CLRB
Price
$5.35
Change
-$0.24 (-4.29%)
Updated
Jul 24 closing price
Capitalization
15.29M
24 days until earnings call
IBRX
Price
$3.01
Change
+$0.02 (+0.67%)
Updated
Jul 24 closing price
Capitalization
2.66B
12 days until earnings call
Interact to see
Advertisement

CLRB vs IBRX

Header iconCLRB vs IBRX Comparison
Open Charts CLRB vs IBRXBanner chart's image
Cellectar Biosciences
Price$5.35
Change-$0.24 (-4.29%)
Volume$165.85K
Capitalization15.29M
ImmunityBio
Price$3.01
Change+$0.02 (+0.67%)
Volume$7.27M
Capitalization2.66B
CLRB vs IBRX Comparison Chart in %
Loading...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLRB vs. IBRX commentary
Jul 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLRB is a Hold and IBRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2025
Stock price -- (CLRB: $5.35 vs. IBRX: $3.01)
Brand notoriety: CLRB and IBRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLRB: 26% vs. IBRX: 85%
Market capitalization -- CLRB: $15.29M vs. IBRX: $2.66B
CLRB [@Biotechnology] is valued at $15.29M. IBRX’s [@Biotechnology] market capitalization is $2.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLRB’s FA Score shows that 0 FA rating(s) are green whileIBRX’s FA Score has 1 green FA rating(s).

  • CLRB’s FA Score: 0 green, 5 red.
  • IBRX’s FA Score: 1 green, 4 red.
According to our system of comparison, IBRX is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLRB’s TA Score shows that 4 TA indicator(s) are bullish while IBRX’s TA Score has 5 bullish TA indicator(s).

  • CLRB’s TA Score: 4 bullish, 6 bearish.
  • IBRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, IBRX is a better buy in the short-term than CLRB.

Price Growth

CLRB (@Biotechnology) experienced а +7.65% price change this week, while IBRX (@Biotechnology) price change was +6.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.05%. For the same industry, the average monthly price growth was +18.11%, and the average quarterly price growth was +28.55%.

Reported Earning Dates

CLRB is expected to report earnings on Aug 18, 2025.

IBRX is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Biotechnology (+6.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.66B) has a higher market cap than CLRB($15.3M). IBRX YTD gains are higher at: 17.578 vs. CLRB (-40.357). CLRB has higher annual earnings (EBITDA): -45.92M vs. IBRX (-264M). CLRB has less debt than IBRX: CLRB (474K) vs IBRX (526M). IBRX has higher revenues than CLRB: IBRX (31.2M) vs CLRB (0).
CLRBIBRXCLRB / IBRX
Capitalization15.3M2.66B1%
EBITDA-45.92M-264M17%
Gain YTD-40.35717.578-230%
P/E RatioN/AN/A-
Revenue031.2M-
Total CashN/A61.6M-
Total Debt474K526M0%
FUNDAMENTALS RATINGS
CLRB vs IBRX: Fundamental Ratings
CLRB
IBRX
OUTLOOK RATING
1..100
39
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9659
P/E GROWTH RATING
1..100
75100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for CLRB (56). This means that IBRX’s stock grew somewhat faster than CLRB’s over the last 12 months.

IBRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLRB (100). This means that IBRX’s stock grew similarly to CLRB’s over the last 12 months.

IBRX's SMR Rating (100) in the Biotechnology industry is in the same range as CLRB (100). This means that IBRX’s stock grew similarly to CLRB’s over the last 12 months.

IBRX's Price Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for CLRB (96). This means that IBRX’s stock grew somewhat faster than CLRB’s over the last 12 months.

CLRB's P/E Growth Rating (75) in the Biotechnology industry is in the same range as IBRX (100). This means that CLRB’s stock grew similarly to IBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLRBIBRX
RSI
ODDS (%)
Bullish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 24 days ago
85%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LCCAX38.35N/A
N/A
Columbia Contrarian Core A
CSVZX38.63N/A
N/A
Columbia Select Large Cap Value Inst
KCVIX18.12N/A
N/A
Knights of Columbus Large Cap Value I
PEDMX13.38N/A
N/A
Principal Edge MidCap R6
UGTIX28.36N/A
N/A
Victory Growth and Tax Strategy Ins